Temporal trends in acute stroke management

Stroke

Volumn 44, Issue SUPPL. 1, 2013, Pages

  Kleindorfer, Dawn ^a   De Los Rios La Rosa, Felipe ^a   Khatri, Pooja ^a   Kissela, Brett ^a   Mackey, Jason ^b   Adeoye, Opeolu ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Epidemiology; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DISEASE SEVERITY; DRUG APPROVAL; HEALTH CARE SYSTEM; HOSPITAL CARE; HUMAN; PRIORITY JOURNAL; UNITED STATES;

EPIDEMIOLOGY; STROKE; THROMBOLYSIS;

BRAIN ISCHEMIA; CASE MANAGEMENT; DRUG UTILIZATION; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 84880270442     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001457     Document Type: Conference Paper

References (12)

1. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Kleindorfer D LC, White G, Curtis T, Brass L, Koroshetz W, Broderick JP. National us estimates of rt-pa use: Icd-9 codes substantially underestimate. Stroke. 2008;39:924-928.
4. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissuetype plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952-1955.
5. Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke. 2009;40:3580-3584.
6. Kleindorfer D, Mullen M, Hogan C, Adeoye O, Khatri P, Jauch E. Primary stroke center certification and its impact on thrombolysis use. Stroke.abstract. 2012.
7. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-e29.
8. Kleindorfer DO, Broderick JP, Khoury J, Flaherty ML, Woo D, Alwell K, et al. Emergency department arrival times after acute ischemic stroke during the 1990s. Neurocrit Care. 2007;7:31-35.
9. Majersik JJ, Smith MA, Zahuranec DB, Sánchez BN, Morgenstern LB. Population-based analysis of the impact of expanding the time window for acute stroke treatment. Stroke. 2007;38:3213-3217.
10. Khatri P KJ, Alwell K, Moomaw CJ, Kissela BM, Woo D, Flaherty ML, et al. T Stroke and Cerebral Circulation, Los Angeles, CA (February 2011). The public health impact of an effective acute treatment for mild ischemic strokes. Stroke.abstract. 2011.
11. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr.; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
12. de Los Rios la Rosa F, Khoury J, Kissela BM, Flaherty ML, Alwell K, Moomaw CJ, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: The effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke. 2012;43:1591-1595.